These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15340759)

  • 1. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Mori K; Fujii H; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):505-13. PubMed ID: 15340759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Schedule-dependent synergism and antagonism between paclitaxel and methotrexate in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Furuta M; Yazawa Y; Ando J
    Oncol Res; 1998; 10(7):347-54. PubMed ID: 10063968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow.
    Das JR; Fryar-Tita EB; Green S; Southerland WM; Bowen D
    Anticancer Res; 2007; 27(2):825-33. PubMed ID: 17465208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro schedule-dependent interaction between paclitaxel and cisplatin in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Yazawa Y
    Cancer Chemother Pharmacol; 1996; 37(6):525-30. PubMed ID: 8612305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro.
    Kano Y; Tanaka M; Akutsu M; Mori K; Yazawa Y; Mano H; Furukawa Y
    Cancer Chemother Pharmacol; 2009 Nov; 64(6):1129-37. PubMed ID: 19306094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Ando J; Tsunoda S
    Breast Cancer Res Treat; 1999 Jul; 56(1):79-90. PubMed ID: 10517345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Suzuki K; Mori K; Yazawa Y; Tsunoda S
    Cancer Chemother Pharmacol; 1999; 44(5):381-8. PubMed ID: 10501911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro schedule-dependent interaction between paclitaxel and SN-38 (the active metabolite of irinotecan) in human carcinoma cell lines.
    Kano Y; Akutsu M; Tsunoda S; Mori K; Suzuki K; Adachi KI
    Cancer Chemother Pharmacol; 1998; 42(2):91-8. PubMed ID: 9654107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Schedule-dependent interactions between pemetrexed and cisplatin in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Izumi T; Kobayashi H; Inoue K; Mori K; Fujii H; Mano H; Odgerel T; Furukawa Y
    Oncol Res; 2006; 16(2):85-95. PubMed ID: 16898269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination studies of antifolates with 5-fluorouracil in colon cancer cell lines.
    van der Wilt CL; Kuiper CM; Peters GJ
    Oncol Res; 1999; 11(8):383-91. PubMed ID: 10803742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic.
    Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro.
    Kano Y; Akutsu M; Tsunoda S; Ando J; Matsui J; Suzuki K; Ikeda T; Inoue Y; Adachi K
    Br J Cancer; 1996 Sep; 74(5):704-10. PubMed ID: 8795571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines.
    Tanaka R; Ariyama H; Qin B; Takii Y; Baba E; Mitsugi K; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):595-601. PubMed ID: 15731917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells.
    Li T; Ling YH; Goldman ID; Perez-Soler R
    Clin Cancer Res; 2007 Jun; 13(11):3413-22. PubMed ID: 17545550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence dependence of Alimta (LY231514, MTA) combined with doxorubicin in ZR-75-1 human breast carcinoma cells.
    Schultz RM; Dempsey JA
    Anticancer Res; 2001; 21(5):3209-14. PubMed ID: 11848474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro sequence-dependent interaction between nedaplatin and paclitaxel in human cancer cell lines.
    Tanaka R; Takii Y; Shibata Y; Ariyama H; Qin B; Baba E; Kusaba H; Mitsugi K; Harada M; Nakano S
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):279-85. PubMed ID: 15875187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
    Liebmann JE; Fisher J; Teague D; Cook JA
    Oncol Res; 1994; 6(1):25-31. PubMed ID: 7919549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
    Tonkinson JL; Worzalla JF; Teng CH; Mendelsohn LG
    Cancer Res; 1999 Aug; 59(15):3671-6. PubMed ID: 10446980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
    Zhao R; Zhang S; Hanscom M; Chattopadhyay S; Goldman ID
    Clin Cancer Res; 2005 Feb; 11(3):1294-301. PubMed ID: 15709201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts.
    Teicher BA; Chen V; Shih C; Menon K; Forler PA; Phares VG; Amsrud T
    Clin Cancer Res; 2000 Mar; 6(3):1016-23. PubMed ID: 10741729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.